Combination of chemotherapy with docetaxel / cisplatin / fluorouracil (DCF) and autologous gamma/delta T cell transfer therapy for esophageal cancer.
Phase 1
- Conditions
- Esophageal cancer
- Registration Number
- JPRN-UMIN000008097
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: -Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; -Treated with chemoradiotherapy; -Active enteritis; -Active autoimmune diseases, -Active infections; -Other cancers; -Other serious complications; -Continuous systemic administration of steroids.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Efficacy -Progression-free survival -Overall survival -Response rate -Survival rate (1 and 2 years) -Response of tumor-related markers -Immunological responses